Acadia Pharmaceuticals Inc. vs. Eli Lilly & Co.
Eli Lilly & Co. (LLY) comes out ahead, leading on 2 of 2 compared factors.
Size & Scale
| ACAD | LLY | |
|---|---|---|
| Market Cap | $5.07 billion | $1.09 trillion |
| Revenue (TTM) | $1.14 billion | — |
| Net Income (TTM) | $380.48 million | — |
LLY leads on 1 of 1 size & scale factors.
Valuation
| ACAD | LLY | |
|---|---|---|
| P/E Ratio | 12.66 | — |
| Price / Book | 3.88 | — |
| Price / Sales | 4.46 | — |
ACAD and LLY split the valuation factors evenly.
Profitability
| ACAD | LLY | |
|---|---|---|
| Net Margin | 33.42% | — |
| Return on Equity | 29.12% | — |
ACAD and LLY split the profitability factors evenly.
Risk & Sentiment
| ACAD | LLY | |
|---|---|---|
| Short Interest | 5.74% | 1.29% |
LLY leads on 1 of 1 risk & sentiment factors.
Dig deeper: ACAD overview, ACAD financials, LLY overview, LLY financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.